research chemical raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-03 and is reviewed periodically as new material appears.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
In its common research form the peptide is supplied as a lyophilized powder. It dissolves readily in water and in typical aqueous buffers, which simplifies preparation of working solutions. Laboratories usually prepare small aliquots instead of one large volume. The dry material appears as a white to off-white solid with no distinctive odor. Bulk quantities are typically shipped in sealed vials.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
=== Ho–Hu === Gladys Lounsbury Hobby (1910–1993), American microbiologist known for development and early understanding of antibiotics Dorothy Hodgkin (1910–1994), British chemist, 1964 Nobel Prize in chemistry for development of protein crystallography Jacobus Henricus van 't Hoff (1852–1911), Dutch physical chemist known for developing the princioles of chemical thermodynamics, 1901 Nobel Prize in Chemistry Albert Hofmann (1906–2008), Swiss chemist, synthesized Lysergic acid diethylamide (LSD) August Wilhelm Hofmann (1818–1892), German chemist, first to isolate sorbic acid Darleane C. Hoffman (1926–2025), American nuclear chemist who studied the properties of transuranium elements Friedrich Hoffmann (1660–1742), German physician and chemist who found that lime, magnesia, etc. existed in almost all mineral springs in Germany Roald Hoffmann (born 1937), Polish-born American chemist, 1981 Nobel Prize in Chemistry for theories of the course of chemical reactions Antonín Holý (1936–2012), Czech medicinal chemist known for acyclic nucleoside phosphonates, including Cidofovir, Adefovir and Tenofovir Mei Hong (born 1970), Chinese-American biophysical chemist known for development solid-state nuclear magnetic resonance to elucidate the structures and mechanisms of membrane proteins Frederick Gowland Hopkins (1861–1947), British biochemist, known for discovery of vitamins, Nobel Prize in Physiology or Medicine in 1929 Marjorie G.
The phase 2 study of LGD-4033 for muscle wasting was finally initiated in November 2016 and was completed with results reported in 2017 and 2018. As of March 2023, LGD-4033 (VK5211) continues to be under development by Viking Therapeutics and continues to be in phase 2 clinical trials for treatment of muscle atrophy and hip fracture.
== hCG preparations == Human chorionic gonadotropin (hCG) can be recovered from the urine of pregnant women or be produced from recombinant DNA. It acts similarly to LH, but the larger supply makes it less costly; it also has a longer half-life. In veterinary medicine, equine chorionic gonadotropin (eCG) extracted from pregnant mare serum is used instead on a variety of mammals, sometimes eliciting an immune response in non-horse species. In Women: Used to induce final maturation of follicle and subsequent ovulation. Also used for luteal phase support. In men: Used to treat select cases of Hypogonadotropic Hypogonadism in adult males. In off-label use, some urologists prescribe hCG in low doses in combination with testosterone replacement to preserve fertility. In male children: Also used to treat prepubertal cryptorchidism not due to anatomical obstruction. Therapy is usually administered between ages 4 and 9.
Sources: en.wikipedia.org
In molecular biology, the ATP:guanido phosphotransferase family is a family of structurally and functionally related enzymes, that reversibly catalyse the transfer of phosphate between ATP and various phosphagens. The enzymes belonging to this family include:
For years I have been endeavouring to find a credible thesis for the development of Buddhist art, and primarily to trace the ancient route by which the art of imperial Rome, etc..., reached the Far East. What I have seen here goes beyond my wildest dreams. If only I had hands enough to copy it all, [for] here in Kizil are about 300 caves, some of them containing frescoes, all of them very old and fine." The French explorer Paul Pelliot and his photographer Charles Nouette, who were in Kucha from January 1907, visited Kizil soon after the German mission, from September 1, 1907, over a few days, and Charles Nouette took many beautiful and informative photographs. Albert von Le Coq came back to Kizil and surrounding areas in 1913–1914, heading the Fourth German Expedition, removing many paintings, including those Grünwedel had left in place, but generally taking much fewer records than his predecessor.
Astatine-210 and most of the lighter isotopes exhibit beta plus decay (positron emission), astatine-217 and heavier isotopes except astatine-218 exhibit beta minus decay, while astatine-211 undergoes electron capture. The most stable isotope is astatine-210, which has a half-life of 8.1 hours. The primary decay mode is beta plus, to the relatively long-lived (in comparison to astatine isotopes) alpha emitter polonium-210. In total, only five isotopes have half-lives exceeding one hour (astatine-207 to -211). The least stable ground state isotope is astatine-213, with a half-life of 125 nanoseconds. It undergoes alpha decay to the extremely long-lived bismuth-209. Astatine has 24 known nuclear isomers, which are nuclei with one or more nucleons (protons or neutrons) in an excited state. A nuclear isomer may also be called a "meta-state", meaning the system has more internal energy than the "ground state" (the state with the lowest possible internal energy), making the former likely to decay into the latter. There may be more than one isomer for each isotope. The most stable of these nuclear isomers is astatine-202m1, which has a half-life of about 3 minutes, longer than those of all the ground states bar those of isotopes 203–211 and 220. The least stable is astatine-213m1; its half-life of 110 nanoseconds is shorter than 125 nanoseconds for astatine-213, the shortest-lived ground state.
Sources: en.wikipedia.org
=== Cancer === After finding that Ras proteins are mutated in 30% of human cancers, it was suspected that mutated Rho proteins might also be involved in cancer reproduction. However, as of August 2007, no oncogenic mutations have been found in Rho proteins, and only one has been found to be genetically altered. To explain the role of Rho pathways without mutation, researchers have now turned to the regulators of rho activity and the levels of expression of the Rho proteins for answers. One way to explain altered signaling in the absence of mutation is through increased expression. Overexpression of RhoA, RhoB, RhoC, Rac1, Rac2, Rac3, RhoE, RhoG, RhoH, and Cdc42 has been shown in multiple types of cancer. This increased presence of so many signaling molecules implies that these proteins promote the cellular functions that become overly active in cancerous cells. A second target to explain the role of the Rho proteins in cancer is their regulatory proteins. Rho proteins are very tightly controlled by a wide variety of sources, and over 60 activators and 70 inactivators have been identified. Multiple GAPs, GDIs, and GEFs have been shown to undergo overexpression, downregulation, or mutation in different types of cancer. Once an upstream signal is changed, the activity of its targets downstream—i.e., the Rho proteins—will change in activity. Ellenbroek et al. outlined a number of different effects of Rho activation in cancerous cells. First, in the initiation of the tumor modification of Rho activity can suppress apoptosis and therefore contribute to artificial cell longevity.
== Public awareness and solutions == Third-hand smoke is a relatively newly postulated and initially controversial concept, and public awareness of it is lower than that of passive smoke. A 2013 study with six focus groups in metro and rural Georgia (USA) asked participants whether they had heard of THS, most of the participants had not heard about it and did not know what third-hand smoke was. Research on THS is growing, but it does not compare to the 40 years of research on the effects of passive smoke. Yet, it is estimated that 5%-60% of passive smoke-related harm may be attributable to third-hand smoke exposure. THS poses such a risk because its exposure can linger much longer than passive smoke. Third-hand smoke-contaminated surfaces like carpet, walls, and car interiors are also especially hard to clean, whereas passive smoke can be removed with ventilation. Smoking rates in the United States have fallen considerably from 42.4% in 1965 to 17.8% in 2016. However, the downward trend is slowing, and it is estimated that 23% to 42% of adults in America with low education or living in poverty still smoke. This exposes millions of nonsmokers, many of whom are children. THS awareness campaigns are growing and primarily focus on the health risks for young children. A 2014 study published in Pediatrics demonstrated that parents are more likely to attempt to quit smoking if they become convinced that third-hand smoke is harmful to children and are more likely to have smoke-free home and car policies if they are aware of the dangers of third-hand smoke.
Beekeeping and Sustainable Livelihoods (2004), Food and Agriculture Organization of the United Nations "Honey" . The New Student's Reference Work . 1914. Dubner, Stephen J.; Levitt, Steve (10 April 2026). "Beeconomics 101". Freakonomics. Episode 670. On the bee, honey, and pollination industry in the United States.
== Types of nuclear warfare == Nuclear warfare scenarios are usually divided into two groups, each with different effects and potentially fought with different types of nuclear armaments. The first, a limited nuclear war (sometimes attack or exchange), refers to the controlled use of nuclear weapons, whereby the implicit threat exists that a nation can still escalate their use of nuclear weapons. For example, using a small number of nuclear weapons against strictly military targets could be escalated through increasing the number of weapons used, or escalated through the selection of different targets. Limited attacks are thought to be a more credible response against attacks that do not justify all-out retaliation, such as an enemy's limited use of nuclear weapons. The second, a full-scale nuclear war, could consist of large numbers of nuclear weapons used in an attack aimed at an entire country, including military, economic, and civilian targets. Such an attack would almost certainly destroy the entire economic, social, and military infrastructure of the target nation, and would likely have a devastating effect on Earth's biosphere. Some Cold War strategists such as Henry Kissinger argued that a limited nuclear war could be possible between two heavily armed superpowers (such as the United States and the Soviet Union). Some predict, however, that a limited war could potentially "escalate" into a full-scale nuclear war.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.